Is Xanax owned by Pfizer?

No. Xanax is owned by Viatris Inc. Pfizer controlled the brand from 2003 to 2020, then spun it off inside the Upjohn division that merged with Mylan to form Viatris in November 2020.

Is Xanax publicly traded?

No. Xanax is a product, not a company. Its owner, Viatris Inc., trades on the Nasdaq under the ticker VTRS.

When was Xanax approved?

The FDA approved Xanax (alprazolam) on October 16, 1981. It was developed by The Upjohn Company and initially indicated for panic disorder, with generalized anxiety disorder added later.

Alprazolam was developed by researchers at The Upjohn Company of Kalamazoo, Michigan. Upjohn merged with Pharmacia in 1995, was absorbed by Pfizer in 2003, and the brand passed to Viatris in 2020.

Is Xanax a controlled substance?

Yes. Xanax is a DEA Schedule IV controlled substance, meaning it has accepted medical use but a recognized potential for dependence and misuse. Prescriptions are tracked through state monitoring programs.

Is generic alprazolam the same as Xanax?

Generic alprazolam contains the same active ingredient and is therapeutically equivalent to branded Xanax. Viatris owns the Xanax trademark; multiple manufacturers produce the generic form.

Healthcare & Pharmaceuticals

Who Owns Xanax?

Xanax is owned by Viatris Inc. (Nasdaq: VTRS), which acquired the brand in November 2020 when Pfizer spun off its Upjohn division and combined it with Mylan. Xanax is the brand name for alprazolam, a Schedule IV benzodiazepine approved by the FDA in 1981 for anxiety and panic disorders. Originally developed by The Upjohn Company, Xanax is the most prescribed benzodiazepine in the United States.

Twitter Facebook LinkedIn

Parent Company

Viatris Inc.

Acquired

2020

Status

Publicly Traded

Headquarters

Canonsburg, Pennsylvania, USA

Xanax Timeline

1981

Xanax

Founded by The Upjohn Company (internal development)

Founded

2020

Acquired by Viatris Inc.

Viatris Inc. acquired Xanax

Acquired

premiumpremiumUnited StatesOfficial Website

Who Owns Xanax?

Parent Company: Viatris Inc.
Ownership Type: Wholly owned
Acquisition Year: 2020
Company Type: Publicly Traded
Stock Ticker: Nasdaq: VTRS

Brand	Parent Company	Ownership Type
Xanax	Viatris Inc.	Wholly owned

Where to Buy

Disclosure: We may earn commission from purchases

Xanax on Amazon

History of Xanax

Founded: 1981
Founders: The Upjohn Company (internal development)
Acquired by Viatris Inc.: 2020

Upjohn chemist David Sheehan and his team developed alprazolam in the late 1960s and early 1970s while searching for a new anti-anxiety agent. The FDA approved Xanax on October 16, 1981, initially for panic disorder. Upjohn promoted it aggressively, and by the mid-1980s Xanax was among the best-selling psychiatric drugs in the United States.

The drug's market position was built on rapid onset of action. Xanax reaches peak blood levels faster than older benzodiazepines such as Valium, which made it effective for panic attacks but also gave it a higher misuse potential. Its 1990 approval for panic disorder expanded the label.

Through the 1990s, Xanax passed from Upjohn into Pharmacia & Upjohn after the 1995 merger, then into Pharmacia Corporation, and into Pfizer when Pfizer bought Pharmacia for about $60 billion in April 2003. U.S. generic entry arrived around the original patent expiry, and generic alprazolam soon captured most prescription volume while the brand retained premium pricing.

In November 2020, Pfizer completed the separation of its Upjohn established-products division and merged it with Mylan to form Viatris. Xanax moved with the deal. Under Viatris, branded Xanax is sold primarily in the United States, where it remains the most prescribed benzodiazepine.

Culturally, Xanax became one of the most referenced pharmaceuticals in American life, appearing in hip-hop lyrics and public debate over benzodiazepine dependence. Counterfeit alprazolam tablets sold as Xanax, often laced with fentanyl, have become a documented public safety concern.

About Viatris Inc.

What does Viatris own?
Viatris owns the Lipitor, Viagra, Xanax, and Eliquis brands, along with a portfolio of over 1,400 approved generic molecules across cardiovascular, respiratory, central nervous system, oncology, immunology, and other therapeutic areas. The company also has a pipeline of complex generics and biosimilars. Its product portfolio was formed through the merger of Upjohn (Pfizer's legacy brand-name drug business) and Mylan (a global generic pharmaceutical company).

Is Viatris publicly traded?
Yes, Viatris Inc. is publicly traded on the Nasdaq stock exchange under ticker VTRS. The company has a dispersed shareholder base with institutional investors holding the majority of shares. Pfizer distributed its Viatris shares to Pfizer shareholders in 2021 and no longer holds a significant ownership stake. Viatris returned more than $1 billion to shareholders in 2025 through share repurchases and dividends.

Who founded Viatris?
Viatris was not founded by individuals. It was created in November 2020 through the merger of Upjohn, a division of Pfizer that held legacy brand-name drugs, and Mylan, a global generic pharmaceutical company founded in 1961 in White Sulphur Springs, West Virginia. The merger combined Upjohn's brand-name portfolio with Mylan's generic manufacturing capabilities to form a new company focused on providing access to affordable medicines.

Where is Viatris headquartered?
Viatris is headquartered in Canonsburg, Pennsylvania, USA. The company maintains its corporate offices in Pennsylvania and operates manufacturing facilities, distribution centers, and sales offices across the world. Its manufacturing network includes facilities in the United States, India, Europe, and China.

How many brands does Viatris own?
Viatris owns four key brand-name medicines: Lipitor, Viagra, Xanax, and Eliquis. The company also owns a portfolio of over 1,400 approved generic molecules across multiple therapeutic areas. In 2025, the company generated approximately $324 million in new product revenues and expects $450 million to $550 million in new product revenues in 2026 from its pipeline of generic and complex generic products.

Who owns Viatris?
Viatris is a publicly traded company with a dispersed shareholder base. Institutional investors, including mutual funds and investment firms, hold the majority of shares. No single shareholder has controlling ownership. Pfizer, the former parent of Upjohn, distributed its Viatris shares to Pfizer shareholders in 2021 and no longer holds a significant stake. The company is governed by a board of directors with independent representation.

What are Viatris's largest brands?
Lipitor and Viagra are Viatris's most recognizable brand-name products. Lipitor is a cholesterol-lowering statin medication originally developed by Pfizer. Viagra is an erectile dysfunction medication also originally developed by Pfizer. Xanax, an anti-anxiety medication, and Eliquis, an anticoagulant, are the company's other major brand-name products. Together, these brands contribute to the Developed Markets segment, which generated $8.5 billion in revenue in 2025.

Founded: 2020
Headquarters: Canonsburg, Pennsylvania, USA
Company Type: Publicly Traded
Stock: Nasdaq: VTRS
Revenue: $14.3 billion (FY2025)
Employees: approximately 32,000

Visit Viatris Inc. website

View full company profile for Viatris Inc.

Where Is Xanax Made / Based?

Headquarters: Canonsburg, Pennsylvania, USA
Manufacturing / Operations: United States

Xanax Categories & Tags

Anxiety Benzodiazepine Prescription Mental Health Viatris Controlled Substance

Xanax Recalls & Controversies

Dependence and withdrawal: Benzodiazepine dependence is a documented clinical concern with Xanax. Its short half-life produces pronounced withdrawal symptoms, which has driven long-running medical and regulatory scrutiny of long-term prescribing.

Counterfeit tablets: Illicitly manufactured alprazolam tablets pressed to resemble Xanax have been documented by the DEA and CDC as a source of fentanyl exposure. These are counterfeit products, not Viatris-manufactured tablets, but they attach reputational risk to the brand name.

Mylan era pricing criticism: Under Mylan, the company that later merged into Viatris, brand pricing practices across the portfolio drew congressional scrutiny, most prominently over EpiPen rather than Xanax itself.

Xanax Ownership: Pros & Cons

Advantages

+Viatris's global commercial infrastructure keeps the branded product distributed through U.S. retail channels
+Four decades of brand recognition sustain premium pricing against generic alprazolam
+Branded products like Xanax generate higher margins than the parent's generic portfolio
+Manufacturing and regulatory expertise for controlled substances is centralized under the parent

Considerations

-Schedule IV status invites regulatory scrutiny that limits marketing and expands compliance costs
-Brand sales are structurally declining as generic alprazolam captures most volume
-Counterfeit "Xanax" in illicit markets creates a public safety association the brand cannot fully control
-Dependence concerns have pushed clinical guidelines toward first-line SSRI alternatives

Frequently Asked Questions About Xanax

Sources & Further Reading

Competitors to Xanax

These competing brands operate in the same categories and provide similar products or services. Compare key attributes to understand market positioning and competitive landscape.

Brand	Parent Company	Country	Founded	Market Position	Primary Market	Gender Target
ZoloftSister Brand	Viatris	USA	1991	Premium	Global	All Genders
CelebrexSister Brand	Viatris	USA	1998	Premium	Global	All-ages
EpiPenSister Brand	Viatris	USA	1987	Premium	Global	All Genders
LipitorSister Brand	Viatris	USA	1996	Premium	Global	All-ages
NorvascSister Brand	Viatris	USA	1992	Mass market	Global	All-ages
ViatrisSister Brand	Viatris	USA	2020	Mass market	Global	All Genders